Cited by 430Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, Noel W., Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal, Loredo, Eugenia, Procopio, Giuseppe, de Menezes, Juliana, Girotto, Gustavo, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Y., Sugimoto, Mikio, Virizuela, Juan A., Emmenegger, Urban, Navratil, Jiri, Buchschacher, Gary L., Poehlein, Christian, Harrington, Elizabeth A., Desai, Chintu, Kang, Jinyu, Saad, Fred·2022·NEJM Evidence

DOI 10.1056/evidoa2200043

Open this paper in CoChat — free account

Abstract

BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled regardless of homologous recombination repair gene mutation (HRRm) status. HRRm status was determined following enrollment by tumor tissue and circulating tumor DNA tests. Patients were randomly assigned (1:1) to receive abiraterone (1000 mg once daily) plus prednisone or prednisolone with either olaparib (300 mg twice daily) or placebo. The primary end point was imaging-based progression-free survival (ibPFS) by investigator assessment. Overall survival was among the secondary end points. RESULTS: At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001) and was consistent with blinded independent central review (hazard ratio, 0.61; 95% CI, 0.49 to 0.74). At this data cutoff, overall survival data were immature (28.6% maturity; hazard ratio, 0.86; 95% CI, 0.66 to 1.12; P=0.29). The safety profile of olaparib and abiraterone was consistent with the known safety profiles of the individual drugs. The most common adverse events in the abiraterone and olaparib arm were anemia, fatigue/asthenia, and nausea. CONCLUSIONS: At primary analysis at this first data cutoff, abiraterone combined with olaparib significantly prolonged ibPFS compared with abiraterone and placebo as first-line treatment for patients with mCRPC enrolled irrespective of HRRm status. (Funded by AstraZeneca and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03732820.)

Integrity signals

Registry

Crossref · 10.1056/evidoa2200043

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citation
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citation
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citation
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citation

Flagged first, then by citations

Show all 27 references

Sorted by citations

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D. A., Bitting, R. L., Bryce, A. H., Chapin, B. F., Cheng, H. H., D'Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 623
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01055-3 · Cited by 538
Self-citation
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Self-citation
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Tilki, D., van den Bergh, R. C. N., Briers, E., den Broeck, T. V., Brunckhorst, O., Darraugh, J., Eberli, D., Meerleer, G. D., Santis, M. D., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 407
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01649 · Cited by 355
Self-citation
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00382-0 · Cited by 326
Self-citation
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Drew, Y., Zenke, F. T., & Curtin, N. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01060-w · Cited by 208
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. Y. L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 183
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen, S., Bossi, A., Davis, I. D., Bono, J. S. D., Fizazi, K. S., James, N. D., Mottet, N., Shore, N. D., Small, E. J., Smith, M. R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.018 · Cited by 174
Self-citation
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02704-x · Cited by 154
Self-citation
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Antonarakis, E. S., Park, S. H., Goh, J. C. H., Shin, S. J., Lee, J., Mehra, N., McDermott, R., Sala‐González, N., Fong, P. C. C., Greil, R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00233 · Cited by 153
Self-citation
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
Fonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45475-w · Cited by 145
Self-citation
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
PARP inhibitors in metastatic prostate cancer
Taylor, A. K., Kosoff, D., Emamekhoo, H., Lang, J. M., & Kyriakopoulos, C. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159557 · Cited by 99
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
Olmos, D., Lorente, D., Alameda, D., Cattrini, C., Romero-Laorden, N., Lozano, R., Lopez-Casas, P. P., Jambrina, A., Capone, C., Broecke, A. M. V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.01.011 · Cited by 94
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
Fallah, J., Xu, J., Weinstock, C., Gao, X., Heiss, B. L., Maguire, W. F., Chang, E., Agrawal, S., Tang, S., Amiri-Kordestani, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02105 · Cited by 86
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
Hatano, K., & Nonomura, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220200 · Cited by 81
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Herencia-Ropero, A., Llop‐Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García‐Galea, E., Moles‐Fernández, A., Pedretti, F., Domènech, H., Rodríguez, O., Guzmán, M., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01370-z · Cited by 80
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 73
BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Cheng, H. H., Shevach, J. W., Castro, E., Couch, F. J., Domchek, S. M., Eeles, R. A., Giri, V. N., Hall, M. J., King, M., Lin, D. W., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2185 · Cited by 63
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Agarwal, N., Azad, A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C. A., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00684-1 · Cited by 61
Self-citation
Advances in the treatment of metastatic prostate cancer
Gebrael, G., Fortuna, G. G., Sayegh, N., Swami, U., & Agarwal, N. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.009 · Cited by 56
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Hussain, M., Kocherginsky, M., Agarwal, N., Adra, N., Zhang, J., Paller, C. J., Picus, J., Reichert, Z. R., Szmulewitz, R. Z., Tagawa, S. T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1402 · Cited by 52
The contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 50
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy
Hope, T. A., Antonarakis, E. S., Bodei, L., Calais, J., Iravani, A., Jacene, H. A., Koo, P. J., Morgans, A. K., Osborne, J. R., Tagawa, S. T., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265952 · Cited by 49
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Fettke, H., Dai, C., Kwan, E. M., Zheng, T., Du, P., Ng, N., Bukczynska, P. E., Docanto, M. M., Kostos, L. K., Foroughi, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104738 · Cited by 48
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
Warner, E. W., der Eecken, K. V., Murtha, A. J., Kwan, E. M., Herberts, C., Sipola, J., Ng, S. W. S., Chen, X. E., Fonseca, N. M., Ritch, E. J., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00692-y · Cited by 47
TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer
Agarwal, N., Fred Saad, C., Azad, A., Mateo, J., Matsubara, N., Shore, N. D., Chakrabarti, J., Chen, H.-C., Lanzalone, S., Niyazov, A., et al. (2023) · Future Oncology · doi:10.2217/fon-2023-0526 · Cited by 45
Self-citation
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review
Maekawa, S., Takata, R., & Obara, W. (2024) · Cancers · doi:10.3390/cancers16030523 · Cited by 49
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers
Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23186 · Cited by 44
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
Fizazi, K. S., Azad, A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, É., Jones, R. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00683-x · Cited by 46
Self-citation
Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa, P., Quhal, F., Pradère, B., Gandaglia, G., Ploussard, G., Leapman, M., Gore, J. L., Paradysz, A., Tilki, D., Merseburger, A. S., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00680-4 · Cited by 43
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer
Azad, A., Kostos, L. K., Agarwal, N., Attard, G., Davis, I. D., Dorff, T. B., Gillessen, S., Parker, C. C., Smith, M. R., Sweeney, C. J., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.01.010 · Cited by 42
Impact of DNA damage repair alterations on prostate cancer progression and metastasis
Lukashchuk, N., Barnicle, A., Adelman, C. A., Armenia, J., Kang, J., Barrett, J. C., & Harrington, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162644 · Cited by 43
Self-citation
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis
Naqvi, S. A. A., Riaz, I. B., Bibi, A., Khan, M. A., Imran, M., Khakwani, K. Z. R., Raina, A., Anjum, M. U., Cobran, E. K., Warner, J. L., et al. (2025) · European Urology · doi:10.1016/j.eururo.2024.12.007 · Cited by 41
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation
Kwan, E. M., Wyatt, A. W., & Chi, K. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054497 · Cited by 40
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers
Cao, P. H. A., Dominic, A., Lujan, F. E., Senthilkumar, S., Bhattacharya, P. K., Frigo, D. E., & Subramani, E. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00869-9 · Cited by 43
The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer
Agarwal, N., Zhang, T., Efstathiou, E., Sayegh, N., Engelsberg, A., Fred Saad, C., & Fizazi, K. S. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113249 · Cited by 38
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Francini, E., Agarwal, N., Castro, E., Cheng, H. H., Chi, K. N., Clarke, N. W., Mateo, J., Rathkopf, D. E., Fred Saad, C., & TOMBAL, B. F. (2024) · European Urology · doi:10.1016/j.eururo.2024.09.008 · Cited by 37
Self-citation
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis
Yang, Z., Wang, K., Ou, Y., Hu, X., Wang, Z., Wang, D., Li, X., & Ren, S. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00689-9 · Cited by 35
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Fizazi, K. S., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., Blanchard, P., Bossaert, F., Castro, E., Comperat, E., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.015 · Cited by 35
Self-citation
Genetic and biological drivers of prostate cancer disparities in Black men
Gong, J., Kim, D. M., Freeman, M. R., Kim, H. L., Ellis, L., Smith, B., Theodorescu, D., Posadas, E. M., Figlin, R. A., Bhowmick, N. A., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00828-w · Cited by 38
PARP inhibitors for prostate cancer
Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
Iannantuono, G. M., Chandran, E. B. A., Floudas, C. S., Choo‐Wosoba, H., Butera, G., Roselli, M., Gulley, J. L., & Karzai, F. H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102623 · Cited by 35
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
Self-citation
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial
Fred Saad, C., Thiery-Vuillemin, A., Wiechno, P., Alekseev, B. Y., Sala, N., Jones, R., Kocák, I., Chiurì, V. E., Jassem, J., Fléchon, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00498-3 · Cited by 32
Self-citation
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Heiss, B. L., Chang, E., Gao, X., Truong, T. M., Brave, M. H., Bloomquist, E. W., Shah, A. B., Hamed, S. S., Kraft, J. B., Chiu, H.-J., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02182 · Cited by 28
Prostate cancer and liquid biopsies: Clinical applications and challenges
Urabe, F., Sumiyoshi, T., Tashiro, K., Goto, T., Kimura, T., & Kobayashi, T. (2024) · International Journal of Urology · doi:10.1111/iju.15441 · Cited by 29
Clinical application of whole-genome sequencing of solid tumors for precision oncology
Kim, R., Kim, S., Oh, B. B.-L., Yu, W. S., Kim, C. W., Hur, H., Son, S., Yang, M. J., Cho, D. S., Ha, T., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01288-x · Cited by 28
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Quinn, Z. L., Leiby, B. E., Sonpavde, G., Choudhury, A. D., Sweeney, C. J., Einstein, D. J., Szmulewitz, R. Z., Sartor, O. A., Knudsen, K. E., Yang, E. S.-H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2526 · Cited by 28
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 28
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
Chehade, C. H., Gebrael, G., Sayegh, N., Özay, Z. İ., Narang, A., Crispino, T., Golan, T., Litton, J. K., Swami, U., Moore, K. N., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21870 · Cited by 28
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Beije, N., Abida, W. M., Antonarakis, E. S., Castro, E., de Wit, R., Fizazi, K. S., Gillessen, S., Hussain, M., Mateo, J., Morris, M. J., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.03.038 · Cited by 27
Advances in PARP Inhibitors for Prostate Cancer
Tisseverasinghe, S., Bahoric, B., Anidjar, M., Probst, S., & Niazi, T. M. (2023) · Cancers · doi:10.3390/cancers15061849 · Cited by 27
De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
Piombino, C., Oltrecolli, M., Tonni, E., Pirola, M., Matranga, R., Baldessari, C., Pipitone, S., Dominici, M., Sabbatini, R., & Vitale, M. G. (2023) · Cancers · doi:10.3390/cancers15204945 · Cited by 25
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Yu, F., Liu, Z., Chen, Y., & He, Z. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02844-7 · Cited by 26
CACA guidelines for holistic integrative management of prostate cancer
Dai, B., Wang, H., Shi, B., Xing, J., Zhu, S., He, Z., Zou, Q., Wei, Q., Bi, J., Bian, J., et al. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00118-4 · Cited by 24
French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance
Ploussard, G., Roubaud, G., Barret, É., Beauval, J.-B., Brureau, L., Créhange, G., Dariane, C., Fiard, G., Fromont, G., Gauthé, M., et al. (2022) · The French Journal of Urology · doi:10.1016/j.purol.2022.07.147 · Cited by 29
Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews
Leaning, D. J., Kaur, G., Morgans, A. K., Ghouse, R., Mirante, O., & Chowdhury, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240864 · Cited by 24
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer
Orme, J. J., Taza, F., Sarkar, N. D., Tewari, A. K., Naqvi, S. A. A., Riaz, I. B., Childs, D. S., Omar, N. S., Adra, N., Ashkar, R., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.11.014 · Cited by 23
Self-citation
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer
Kwon, D. H.-M., Gordon, K. M., Tong, B., Borno, H. T., Beigh, M., Fattah, D., Schleicher, A., Aggarwal, R. R., Blanco, A. M., Small, E. J., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00638 · Cited by 23
How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy
Sciarra, A., Santarelli, V., Salciccia, S., Moriconi, M., Basile, G., Santodirocco, L., Carino, D., Frisenda, M., Pierro, G. B. D., Giudice, F. D., et al. (2024) · Cancers · doi:10.3390/cancers16040764 · Cited by 21
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Kostos, L. K., Tran, B., & Azad, A. (2024) · Drugs · doi:10.1007/s40265-024-02071-y · Cited by 22
Utilization of genetic testing in men with advanced prostate cancer
Aguiar, J., Li, E. V., Siddiqui, M. R., Soliman, M., Kumar, S. K. S., Schaeffer, E. M., Keeter, M. K., Brown, C. H., Szymaniak, B. M., & Ross, A. E. (2023) · The Prostate · doi:10.1002/pros.24480 · Cited by 21
Emerging treatment options for prostate cancer
Atiq, M. O., Chandran, E. B. A., Karzai, F. H., Madan, R. A., & Aragon‐Ching, J. B. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2208352 · Cited by 21
Management of Advanced Prostate Cancer in the Precision Oncology Era
Gillette, C. M., Yette, G. A., Cramer, S. D., & Graham, L. S. (2023) · Cancers · doi:10.3390/cancers15092552 · Cited by 21
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium
Mehralivand, S., Thomas, C., Puhr, M., Claessens, F., van de Merbel, A. F., Dubrovska, A., Jenster, G. W., Bernemann, C., Sommer, U. J., & Erb, H. H. H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04878-5 · Cited by 22
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
Al-Akhras, A., Chehade, C. H., Narang, A., & Swami, U. (2024) · Life · doi:10.3390/life14020198 · Cited by 20
The Landscape of PARP Inhibitors in Solid Cancers
Muzzana, M., Broggini, M., & Damia, G. L. M. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s499226 · Cited by 19
Advances in Targeted Therapy for Metastatic Prostate Cancer
Grewal, K., Dorff, T. B., Mukhida, S. S., Agarwal, N., & Hahn, A. W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01323-7 · Cited by 20
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Huang, F., Li, K., Shevach, J. W., & Wang, Q. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.04.004 · Cited by 18
Poly(adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m eta‐analysis
Sayyid, R. K., Klaassen, Z. W. A., Berlín, A., Roy, S., Brandão, L. R., Bernardino, R. M. M., Chavarriaga, J., Jiang, D., Spratt, D. E., Fleshner, N. E., et al. (2023) · British Journal of Urology · doi:10.1111/bju.16130 · Cited by 18
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Maiorano, B. A., Giorgi, U. D., Verzoni, E., Maiello, E., Procopio, G., Conteduca, V., Maïo, M. D., & the MeetURO group (2023) · Targeted Oncology · doi:10.1007/s11523-023-01016-x · Cited by 19
Self-citation
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States
McKay, R. R., Morgans, A. K., Shore, N. D., Dunshee, C. J., Devgan, G., & Agarwal, N. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102726 · Cited by 18
Self-citation
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial
Clarke, N. W., Armstrong, A. J., Oya, M., Shore, N. D., Procopio, G., Guedes, J. D., Arslan, Ç., Mehra, N., Parnis, F. X., Brown, E., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.09.013 · Cited by 18
Self-citation
PARP Inhibitors in the Neoadjuvant Setting; A Comprehensive Overview of the Rationale for their Use, Past and Ongoing Clinical Trials
Habaka, M., Daly, G. R., Shinyanbola, D., Alabdulrahman, M., McGrath, J., Dowling, G. P., Hehir, C. M., Huang, H. Y. R., Hill, A. D. K., Varešlija, D., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01669-z · Cited by 17
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis
Fazekas, T., Széles, Á. D., Teutsch, B., Csizmarik, A., Vékony, B., Kói, T., Ács, N., Hegyi, P., Hadaschik, B. A., Nyírády, P., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.09.001 · Cited by 18
Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer
Marshall, C. H., Gondek, L. P., Daniels, V. A., Lu, C., Paşca, S., Xie, J., Markowski, M. C., Paller, C. J., Sena, L. A., Denmeade, S. R., et al. (2024) · The Prostate · doi:10.1002/pros.24712 · Cited by 17
New Therapeutic Options for BRCA Mutant Patients
Ghanem, A., & Domchek, S. M. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-082523-083843 · Cited by 17
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer
LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16
DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies
Dariane, C., & Timsit, M. (2022) · European Surgical Research · doi:10.1159/000526415 · Cited by 18
Personalized Systemic Therapies in Hereditary Cancer Syndromes
Mastrodomenico, L., Piombino, C., Riccò, B., Barbieri, E., Venturelli, M., Piacentini, F., Dominici, M., Cortesi, L., & Toss, A. (2023) · Genes · doi:10.3390/genes14030684 · Cited by 17
Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor Microenvironment
Inoue, T., Sekito, S., Kageyama, T., Sugino, Y., & Sasaki, T. (2023) · Cancers · doi:10.3390/cancers15092662 · Cited by 16
Circulating Tumor DNA in Prostate Cancer: A Dual Perspective on Early Detection and Advanced Disease Management
Kopytov, S., Sagitova, G. R., Guschin, D. Y., Egorova, V. S., Zvyagin, A. V., & Rzhevskiy, A. S. (2025) · Cancers · doi:10.3390/cancers17152589 · Cited by 17
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
Hiemenz, M., Graf, R. P., Schiavone, K., Harries, L., Oxnard, G. R., Ross, J. S., & Huang, R. S. P. (2022) · The Oncologist · doi:10.1093/oncolo/oyac181 · Cited by 15
Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair
Herberts, C., Wyatt, A. W., Nguyen, P. L., & Cheng, H. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390384 · Cited by 15
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study
Xie, J., Guo, H., Dong, B., Chen, W., Jin, C., Xu, Q., Ding, L., Liu, W., Dong, S., Zhao, T., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.02.005 · Cited by 15
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
Miller, C. D., Likasitwatanakul, P., Toye, E., Hwang, J. H., & Antonarakis, E. S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2405103 · Cited by 15
Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15
Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease
Elsesy, M. E., Oh‐Hohenhorst, S. J., Oing, C., Eckhardt, A., Burdak‐Rothkamm, S., Alawi, M., Müller, C., Schüller, U., Maurer, T., Amsberg, G. V., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13382 · Cited by 14
[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
Satapathy, S., Yadav, M. P., Ballal, S., Sahoo, R. K., & Bal, C. S. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06677-y · Cited by 16
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial
Fred Saad, C., Armstrong, A. J., Oya, M., Vianna, K., Özgüroğlu, M., Gedye, C. A., Buchschacher, G. L., Lee, J. Y., Emmenegger, U., Navrátil, J., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.03.006 · Cited by 16
Self-citation
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?
Garofoli, M., Maiorano, B. A., Bruno, G., Giordano, G., Tullio, P. D., Maselli, F. M., Landriscina, M., & Conteduca, V. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241258443 · Cited by 15
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Azad, A., Fizazi, K. S., Matsubara, N., Fred Saad, C., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Jones, R. J., Zschäbitz, S., Oldenburg, J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115078 · Cited by 14
Self-citation
Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer
Tolkach, Y., Kremer, A., Lotz, G., Schmid, M. C., Mayr, T., Förster, S., Garbe, S., Hosni, S., Cronauer, M. V., Kocsmár, I., et al. (2022) · Cancers · doi:10.3390/cancers14184441 · Cited by 14
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
Sooi, K. W. X., Walsh, R., Kumarakulasinghe, N. B., Wong, A., & Ngoi, N. Y. L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.48 · Cited by 14
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer
Mitsogianni, M., Papatsoris, A., Bala, V.-M., Issa, H., Moussa, M. J., & Mitsogiannis, I. C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2244415 · Cited by 13
Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer
Bugoye, F. C., Torrorey-Sawe, R., Biegon, R., Dharsee, N. J., Mafumiko, F. M. S., Patel, K. T., & Mining, S. K. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1231536 · Cited by 16
Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
Giesen, A., Baekelandt, L., Devlies, W., Devos, G., Dumez, H., Everaerts, W., Claessens, F., & Joniau, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1265812 · Cited by 13

Authors: Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Virizuela, J. A., Emmenegger, U., Navratil, J., Buchschacher, G. L., Poehlein, C., Harrington, E. A., Desai, C., Kang, J., & Saad, F.
Affiliations: University of Manchester (GB)
Duke University (US)
Centre Hospitalier Universitaire de Besançon (FR)
Keio University (JP)
Carolina Urologic Research Center (US)
Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Hospital Nossa Senhora da Conceição (BR)
Hospital de Base (BR)
Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
Radboud University Medical Center (NL)
Ashford Cancer Centre Research, Adelaide, South Australia
University Hospital Southampton NHS Foundation Trust (GB)
Centre Hospitalier de Cornouaille (FR)
National Cancer Center (KR)
Kagawa University Hospital (JP)
Hospital Universitario Virgen Macarena (ES)
Sunnybrook Research Institute (CA)
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Kaiser Permanente (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
Centre Hospitalier de l’Universite de Montreal, Montreal
ORCID: Clarke, Noel W.
Armstrong, Andrew J.
Thiery-Vuillemin, Antoine
Oya, Mototsugu
Shore, Neal
Procopio, Giuseppe
Girotto, Gustavo
Mehra, Niven
Joung, Jae Y.
Sugimoto, Mikio
Virizuela, Juan A.
Emmenegger, Urban
Buchschacher, Gary L.
Poehlein, Christian
Harrington, Elizabeth A.
Kang, Jinyu
Venue: NEJM Evidence
Publisher: Massachusetts Medical Society
Published: 2022-08-23
Volume: 1
Issue: 9
Pages: EVIDoa2200043-EVIDoa2200043
ISSN: 2766-5526 (ISSN-L)
DOI: 10.1056/evidoa2200043
OpenAlex: W4281770555
Cited by: 426
References: 27
Citations by year: 2026: 77 · 2025: 108 · 2024: 111 · 2023: 110 · 2022: 20
FWCI: 56.30
Type: journal article
Language: en
Open access: closed
Locations: NEJM Evidence (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: abiraterone, olaparib, metastatic castration-resistant prostate cancer, PARP inhibitors, first-line therapy, homologous recombination deficiency, progression-free survival, overall survival, combination therapy, PARP inhibitor resistance, circulating tumor DNA, anemia, fatigue, nausea, hormone therapy
MeSH terms: Androstenes, Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks